# A new dioxolanic compound and its method of preparation a new dioxolanic amine with pharmacological activity, its method of preparation, and the pharmaceutical compositions containing them.

## Abstract
A new dioxolanic amine with pharmacological activity of the following structural formula I

## Claims
CLAIMS 1. A new dioxolanic amine with pharmacological activity, of the structural formula I, as under EMI21.1 corresponding to the 2 2 benzofuranil 4 n butylaminomethyl 2 p chlorophenyl 1,3 dioxolane also referred to under the reference ITA 362 , as well as its pharmaceutically acceptable salts such as male ate, citrate, orotate, oxolate malonate, p toluensulphate and the like. 2. The method of preparation of the new dioxolanic amine with pharmacological activity of the general formula I as has been defined in the Claim 1, characterized by starting from a new brcrrornethyl dioxolanic derivative of the structural formula IIEMI21.2 corresponding to the 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1,3 dioxolane which is treated withn butylamine in an inert anhydrous solvent, preferably an aromatic hydrocarbon such as benzene, toluene or xylene and in the pres ence of an acidity acceptor at the boiling point temperature of the mixture during a period varying from between 5 to 50 hours after which the mixture is allowed to cool a solution of sodium or potassium hydroxides is added the organic phase is then de canted, washed and dried, and the solvent removed, product I being obtained thus, in the form of an oil which can subsequently be purified by distillation at a reduced pressure or by the formation of solid salts by treating with an acid in a suitable solvent. 3. The method as in claim 2. characterized inso far as the acidity acceptor utilized in the reaction for the 15 preparation is the n butylamine itself, it being required to use at least two mols. of this for each mol. of bromomethyl derivative t 4. The method as in claim 2. characterized inso far as the acidity acceptor utilized in the preparation react 20 ion is a tertiary amine such as triethylamine or pyridine. 5. The method as in claim 2. characterized inso far as the acidity acceptor utilized in the preparation react ion is an inorganic base such as anhydrous sodium or potassium carbonate. 6. The method as in any of the claims 2 to 5, characterized in that the final compound I is purified by means of the formation of salts treating the base with an acid, preferably a weak organic acid such as maleic, citric, orotic, oxalic, malonic, p toluensuphonic, or the like, within a suitable organic solvent such acetone, methanol, ethanol, isopropanol, chloroform, ethyl acetate, benzene, and in general any organic solvent which satisfactorily dissolves the dioxolanic compound then separating off the solid salt which is formed, by filtration, this being more convenient for future handling and use. 7. The method as in claim 6. characterized because when the acid used has at the same time geometric and optical isomerism, as is the case with maleic and fumaric acids, on the formation of the corresponding salts, the two possible diastereoisomers are separated by fractional crystallization obtaining in this manner the resolution of the isomers. 8. A new dioxolanic compound of the following structural formula II EMI23.1 corresponding to the 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1,3 dioxolane. 9. The method for the preparation of a new dioxolanic compound of structural formula II, as has been defined in claim 8. characterized by starting from the Ketone of formula IIIEMI24.1 dissolved in a chloro solvent such as methylene chloride, chloroform or carbon tetrachloride and at a low temperature, preferably between 0 and 5 deg. C. with a quantity of between one and three times mol. with respect to the Ketone III of epibromhydrine and a Lewis acid as catalyst, then completing the reaction at temperatures of between ambient and that of the boiling point of the mixture during a period varying between 2 and 24 hours, proceeding then to separating the new bromomethyl dioxolanic derivative of formula II. 10. The method as in claim 9. characterized in that the Lewis acid utilized as a catalyst is tin tetrachloride in a quantity of the order of one tenth part mol with respect to the epibromhydrine. 11. The method as in claim 9. characterized in that the Lewis acid utilized as a catalyst is borontrifluoride in a quantity of the order of one tenth part mol. with respect to the epibromhydrine. 12. The method as in claim 9. characterized in that the Lewis acid utilized as catalyst is anhydrous aluminium trichloride in a quantity of the order of one tenth part mol. with respect to the epibromhydrine. 13. The method as in any of the claims 9 to 12, characterized in that the said compound II has two geometric isomers due to the rigidity that the dioxolanic ring produces in the molecule, its proportion being reflected through the nuclear magnetic resonance signal of the furanic proton and which corresponds to the structures of the type IV and V hereunder EMI25.1 14. A pharmaceutical composition characterized by its containing as active ingredient the new dioxolanic amine with pharmacological activity of general formula I, defined in the claim 1. 15. A pharmaceutical composition characterized by its containing as active ingredient the new dioxolanic amine with pharmacological activity of general formula I, obtained by carrying out the procedure according to any of the claims 2 to 7. 16. A pharmaceutical composition according to either of the claims 14 or 15, characterized by its use in the treatment of angina pectoris, stenocardia and acute visceral pain, prophylaxis of the effort, stress, and nocturnal angor, treatment in the recuperation stage of miocardiac infarct, treatment in the cases of cogestive insufficiency of the left ventricular, pulmonary oedema, heart surgery, anaesthesia supra ventricular and ventricular arrythmai, arrythmia resistant to the classic treatments, sinus and proxysmal tachycardia, auricular and flutter fibrillation, nodal and vent ricular tachycardia, ventricular and auricular extra systoles and the Wolf Parkinson White syndrome.

## Description
A new dioxolanic compound and its method of preparation a new dioxola.nic amine with pharmacological activity, its method of preparation, and the Pharmaceutical compositions containing them.INTRODUCTIONThis present invention refers to a new dioxolanic amine with pharmacological activity which has been allocated the reference ITA 362, for brevity.This new compound has the following formula IEMI1.1 corresponding to the 2 2 benzofuranil 4 n butilaminomethyl2 p chlorophenyl l, 3 dioxolan. Equally objects of the invention are the pharmaceutically acceptable salts of the said compoundITA 362, such as maleate, citrate, orotate, oxalate, malonate, p toluensulphate and the like.The invention also refers to the method of preparation of the aforementioned compound ITA 361. The new compound ITA 362 possesses intense vasodilatory, anti angina and anti arrhythmic activity, accompanied by a low toxicity. The use of the compound ITA 362 is another object of the invention.NOVELTY OF THE STARTING PRODUCTAs will be explained in detail further on in the description of the chemical synthesis, in order to prepare the compoundITA 362 one starts off from the dioxolanic derivative bromo methyl of formula II of which the structure is the following EMI2.1 In fact thins compound II is the 2 2l benzofuranil 4 bromo methyl 2 p chlorophenyl l, 3 dioxolan, which was obtained for the first time by the same inventors during the process of the research that led to to the preparation of the compound ITA 362.Hence the said compound, of formula U is a new product as also following logically, is its method of preparation.The invention refers also to this new product of formula II which is an intermediate compound in the preparation of the formula I compound. The other object of the invention is the method of preparation for the formula II compound. CHEMICAL SYNTHESISThe said compound ITA 362 as in formula I is synthesized chemically by means of a two stage process, these being a first stage having for its object the preparation of formula II, that is to say 2 2 benzofuranil 4 bromomethyl Z chlorophenyl 1, 3 dioxolane.b second stage having for its object the preparation of the compound ITA 362 starting off from formula II.Nevertheless, both stages, first and second, though having their individual identities, together form one unity of invention.The two said stages are described in detail further on.First stageThe preparation of the bromomethyl dioxolanic derivative of the formula II, that is the 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1, 3 dioxolane, takes place from starting with the Ketone of formula IIIEMI3.1 in a reaction of which the scheme is the following EMI4.1 To a solution of Ketone III in a chloro solvent such as methylene chloride, chloroform or carbon tetrachloride is added at low temperature, preferably around 0 50C a quantity of between 1 and 3 times mol. with respect to theKetone III of epibromhydrine. Then add slowly the catalyst corresponding to a Lewis acid preferably tin tetrachloride, boron trifluoride or anhydrous aluminium trichloride in a quantity of the order of one tenth part mol. with respect to the epibromhydrine, maintaining the mixture at a low temperature during the addition.Then reaction is completed at a temperature of between the ambient and that of the boiling point of the mixture during a suitable time from 2 to 24 hours .Having completed the reaction a solution of sodium or potassium hydroxide is added quickly up to basic pH, then, the organic phase is decanted, washed, dried and the solvent removed. The residue thus obtained is distilled at a reduced pressure. The structure of this new product corre sponds to the 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1,3 dioxolane, which has two isomers due to the rigidity produced in the molecule by the dioxolanic ring. These isomers are reflected by the nuclear magnetic resonance signal of the furanic proton.This type of isomer is described in great detail for systems similar to ours by P.Calinaud and J.Gelas Bull.Soc. Chem.Fr. 5 6, 1228 1236 and 1237 1242, 1975 and if we take as the principal substituen in the position 2 of the dioxolanic ring the benzofuranil residue, the structures IV and V as shown in the following schemes, are formed EMI5.1 The product so obtained is used for the following or second stage. Second StageThe preparation of the ITA 362 is done starting from the 2 2 benzofuranil 4 br omomethyl 2 p chlorophenyl 1,3 dioxolane of EMI6.1 The 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1,3 dioxolane is caused to react with n butylamine in an inert anhydrous solvent such as benzene, toluene or xylene at the boiling point temperature of the mixture during the time required to complete the reaction from 5 to 50 hours and in the presence of an acidity acceptor.As the acidity acceptor the same n butylamine may be used, using at least 2 mols of this for each mol of the bromomethyl derivative. Equally may be used as acidity acceptor a tertiary amine such as triethylamine or pyridine, or even in inorganic base such as anhydrous sodium or potassium carbonate.After the reaction is completed a solution of sodium or potassium hydroxide is added quickly, then, the organic phase is decanted, washed, dried, and the solvent removed yielding the product in the form of a reddish yellow oil which can be purified by distillation at a low pressure. Treatment with an acid, preferably a weak organic acid such as maleic, citric, orotic, fumaric, malonic, acetic, p toluensuphonic or similar acid, in a suitable organic solvent such as acetone methanol, ethanol, isopropanol, chloroform, ethyl acetate, benzene, and in general any organic solvent which would adequately dissolve the dioxolanic compound, allows t9 obtain a saline solide derivative which is more convenient for future handling and use. When the acid used has at the same time geometric .or optical isornerism as is the case with maleic and fumaric acid, on the formation of the corresponding salts one can separate by fractional crystallization the two diastereoisomers which may be present, thus obtaining by this means the resolution of the isomers.EXAMPLESPreliminary example first stage We describe below an example of the preparation of the 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl l , 3 dioxolane . To a solution of 136 g 0,.53 m of p chlorobenzoil 2 benzo furane in 2000 cc of anhydrous chloroform at 0 5 deg.C is added 109 g 0,80 m of epibromhydrene. Then is added slowly 45 minutes 9,4 cc 0,08m of tin tetrachloride dissolved in 35 cc of anhydrous chloroform.Having terminated the addition above, leave to attain the room temperature and keep stirring during 15 h lr.s, By means ofTLC eluent benzenelhexane 4 1 the progress of the reaction can be controlled.Quickly add 32 g of NaOH dissolved in 100 cc of water ensuring that the final pH is basic and stir during 30 minutes. Decant, wash the organic phase with water until the washings are neutral pH, dry the chloroformic solution with Na2SO4 and elliminate the solvent at a low pressure obtaining 224 g of a yellowish oil. molecular distillation at 145 deg. C and approximately 10 2 mm Hg, yields 143 g 69 . of a slightly yellow oil. A further distillation of the residue of the previous operation yields a further 41 g. total yield 88 .Halogens Schoninger experimental 28, 84 theoretical 29,30. IR film Characteristic bands at 1595, 1490, 1450, 825 and 750 cm1. NMR CDCl3 E 7,75 6,85 m,8, aromatics 6,65 and 6,55 two singlets corresponding to the furanic proton for the cis and the trans isomers 4,80 3,20 m,5, althatics . The experimental ratio of the aliphaticlaromatic integrals theoretical 0,555 is a very significant analytic measurement for testing the quality of the resulting product.EM Molecular peak at m e 392 and 394 with an isotopic ratio suiting a bromo atom and an chloro atom.The product so obtained is ready for the aforementioned second stage leading to the preparation of the 2 2 benzofuranil 4 n butylaminomethyl 2 p chlor ophenyl 1, 3 dioxolane. Should in any instance the reaction has not been coitiplete, most of the unreacted product may be elliminated by precipitation with cyclohexane and if necessary carrying out a previous distillation at 130 deg. C and 10 mm Hg to remove the more volatile components. Examples of the preparation procedure for obtaining the new dioxolanic amine of formula I ITA 362 and its salts are described below, this being the second stage thereof, with all the details not affecting the essentiality of the invention being variables and not limitive to the same.Example 1. Preparation of the 2 2 benzofuranil 4 n but ylaminomethyl 2 p chlor ophenvl 1.3 dioxolane. Equally corresponds to the reference ITA 362 A solution of 266 g 0,676 m of 2 2 benzofuranil 4 bromomethyl 2 p chlorophenyl 1,3 dioxolane and 400 cc 4,06 m of n butylamine in 1000 cc of anhydrous toluene is set to boil during 30 h. By means of TLC eluent AcOEt the progress of the reaction can be controlled. Leave to cool and quickly add 330 cc of NaOH 2N and stir during 30 minutes. Decant, sh thoroughly the organic phase with water to remove the excess n butylamine and elliminate the the solvent at a low pressure, obtaining 255 g 98 of a very thick reddish oil.This product is of a quality suitable fa the subsequent preparation of the salts. If required, further purification may be carried out by molecular distillation 2 at 175 deg.C and 3 4.10 mm Hg yielding 221 g 85 of a very thick yellowish oil.Potentiometric evaluation of basic groups 103 IR film characteristic bands at 1600, 1450, 1250, 1090, 830 and 755 cm l NMR CDCl3 6 7,80 6,85 m, 8, aromatics 670 and 6,55 two singlets corresponding to the furanic proton for the cis and trans isomers 4,80 3,80 m, 3, O CH2 CH 0 3,00 2,45 m, 4, CH2NH CH2 1,80 0,70 m, 7, CH2CH2CH3 . The aminic proton may appear as a singlet with i approx. 2,22,5 or even included within the other signals in this zone in the form of a wide signal.EM molecular peak at m e 385.The preparation of salts of the 2 2 benzofuranil 4 n butylaminemethyl 2 p chlorphenyl 1 ,3 dioxolane. ITA 362 Because the ITA 362 base is an oil it is more convenient for its manipulation and usage to be converted to a solid salt by treating it with a suitable acid. Due to the instability of the dioxolanic compounds in an acqueous acid medium it is preferable to use for its salification weak acids such as maleic, citric, orotic, acetic, fumaric, oxalic, malonic, p toluensulphonic, or similar in any adequate organic solvent such as acetone, methanol, ethanol, isopropanol, chloroform ethyl acetate, benzene and in general any solvent which would adequately dissolve the amine.When the acid used has at the same time geometric or optical isomerism, in the formation of the corresponding salt, one of the two diastereoisomers may be preferably separated by crystallization. Such is the case with maleate of which we detail the preparation below by way of example, with the analytical physical data of the other salts as well. Example 2. Preparation of the maleate of the ITA 362. rO a solution of 166 g 0,43 m of ITA 362 in 400 cc of acet one at 40 50 deg.C is added . 50 g 0,434 m of maleic acid dissolved in acetone at the same temperature. The mixture is stirred and immediately a white solid starts separating out antil it forms a compact mass. Leave it to cool, filter it, wash it with acetone and vacuum dry on C12Ca, obtaining 134 g 627to of a white crystalline solid. Melting point m.p. 163 i64 deg.C. Potentiometric evaluation of the acid groups 100, 0 Potentiometric evaluation of the basic groups 101,0 IR KBr characteristic bands at 1580, 1480 1450, 1360, 1090, 1020 970 and 760 cm 1. NMR d6 DMSO The spectrum with minor variations in the displacement and in the form of the signals is very sim ilar to that of ITA 362 base except for a new signal at 6,3 ppm corresponding to the olefin protons of the maleic acid and signals of furanic proton which appear as two singlets at 6,70 and 6,55 ppm in the free base. While in the base both signals have a similar intensity, with only the most deshielcled being slightly more intense, 10 20 in the salt this signal clearly predominates with respect to the other in a proportion of 3 1. Concentrating the mother liquid Until alraDst dress and crystal izing anew with ethyl acetate one obtains 38 g 18 of a white crystalline solid. m.p. 143 143,5 deg.C. Potentiometric evaluation of the acid groups 100, 801o Potentiometric evaluation of the basic groups 99, logo IR KBr A spectrum very similar to that of the first fraction with minor sariations, though significant, in the form and the intensity of the bands.NMR d6 DMSO A spectrum practically identical to the first fraction except for the signals corresponding to the furanic proton. In this case the signal at 6,55 ppm undoubtedly predominates, in the proportion of 4 1.Example 3. Preparation of orotate of the ITA 362On heating with reflux in ethanol a ste chiometric mixture of the ITA 362 base and orotic acid,a white crystalline solid separates out in parallel with the transformation of the acid that. previously has not completely dissolved.m. p. 235 6 deg. C d .IR KBr characteristic bands at 1710, 1630, 1410, 1100 l and 775 cm Working in a manner generally similar to that indicated above, and in accordance with well established techniques one obtains the citrate, oxalate, malonate and the p toluensulphonate of theITA 362 and for. which the analytical data is given in the following examples.Example 4. Preparation of the citrate of the ITA 362The citrate is a yellowish highly hygroscopic product.m.p. commences to soften at 52 deg.C, decomposing at 900 C.Potentiometric evaluation of the basic groupa 103,4 Example 5. Preparation of the oxalate of the ITA 362.m.p. 178 180 deg.C IR KBr characteristic bands at 1720 tp 1700, 1475, l 1455, 1255, 1165 and 1090 cm Example 6. Preparation of the malonate of the ITA 362.m.p. 111 114 deg.C.IR KBr characteristic bands at 1720 1600, 1490, l 1455, 1090, 830 and 760 cm Example 7. Preparation of the p toluensulphonate of the ITA 362 m.p. 99 103 deg.C.IR KBr characteristic bands at 3390, 1490, 1455, 1190, l 1040, 1020, 820, 760 and 690 cm Obviously, in connection with the above examples all details which do not affect the essentiallity Of the invention may be varied without implying any limitation on the same. PHARMACOLOGICAL ACTIVITYAcute toxicityThe acute toxicity of the ITA 362 with both oral and intra peritoneal administration in the mouse and the rat has been studied using as reference the Amiodarona The MerckIndex, 9th edition,. Merck Co. page 498, 1976 administered under the same conditions.The respective lethal dose 50 was calculated according to the method of Litchfield and Wilcoxon J1. Pharmacol. Exptl. 96 99, 1949 . The values obtained are shown in the tables 1, and 2 given below.Table 1. Acute toxicity of ITA 362 in the rat and in the mouse Oral administration.EMI14.1 tb Treatment SEP Species SEP LD50 SEP in SEP mg kg tb ITA SEP 362 SEP maleate SEP Rat SEP SEP 4000 tb ITA SEP 362 SEP maleate SEP Mouse SEP . SEP SEP SEP 4000 tb Amiodarona SEP Mouse SEP SEP 4000 tb Table 2. Acute toxicity of ITA 362 in the rat and in the mouse Intraperitoneal administration.EMI14.2 tb Treatment SEP Species SEP ZD30 SEP and SEP confidence tb SEP limits SEP in SEP mglkg. SEP tb ITA SEP 362 SEP maleate SEP Rat SEP 105 SEP 83 133 tb Amiodarona SEP Rat SEP 885 SEP 776 1010 tb ITA SEP 3 62 SEP maleate SEP Mouse SEP 106 SEP 102 110 SEP tb Amiodarona SEP Mouse SEP 940 SEP 813 1086 tb Vasodilatory, antiangina and anti arrythmic activityIn the table 3 is shown the results of the vasodilatory activity of the ITA 362 in the perfusion test of the hindquarters of rats with a hyperpotasemic solution. F.N.Fastier, F.M.Smirk. J1. Pharmacolog. Exp. Therapy. 89. 256, 1947 .The activity turned out to be similar to that of the nitroglycerine which was used as the reference thus demonstrating clearly the power of the compound.The antiangina activity was also compared with that of the nitroglycerine by means of the amplitude increase protection test of the T wave for vasopression in the conscious dog. A. Lindner, M.London, G.Werner, Scheiz. Med.Wsohr. 8S, 360, 1953 J.Papp, L. Szekeres. Arch. Int.Pharmacodyn. 160, 1, 1966 . The dose of 1 mg kg with intravenous administration of the ITA 362 shows almost a 50 protection, its activity being greater than that of nitroglycerine which was used as the reference at a dose of 0,4 mg kg, The results are shown in the table 4.Tables 5 and 6 show the anti arrithmic activity of theITA 362 in the male NMRI mouse by oral and intraperitoneal route using the fibrillation test by chloroform in the mouse. V.W.Lawson, J.Pharmacol. Exp. Ther. 160, 22, 1968 B.Vargaftig, J.L.Coignet. Eur.J.Pharmacol. 6 , 49, 1969 In this test amiodarona was used as the reference and was compared with the activities of the various salts of the ITA 362.The activity of the two forms of maleate described in the example 2 were studied and which in the table are subtitled as isomer A corresponding to the first fraction obtained in the a√≤remeiitioned example , and isorer B corresponding to the second fraction. The calculated ED50 are similar there being no significant statistical difference between either the two isomers or in relation to the citrate. Table 6 illustrates that the activity is comparable to that of the amiodarona.Table 3. Vasodilatory activity. Perfusion of the hind quarters of rats with a hyper potasemic solution.EMI16.1 tb Treatment SEP Concent SEP No. SEP of SEP SEP drop SEP in SEP ED SEP 25 tb SEP ration SEP in SEP animals SEP pressure SEP mg kg SEP tb SEP 10 5 SEP 10 SEP 25,4 SEP tb SEP Nitro SEP 10 6 SEP 16 SEP 24,7 SEP 4,6 SEP . SEP 10 6 SEP tb glycerine SEP 10 7 SEP SEP 6 SEP 17,5 SEP r SEP SEP 0,9590 tb SEP 10 8 SEP 7 SEP 10,9 tb SEP 10 5 SEP 7 SEP 33,6 tb ITA SEP 362 SEP 10 6 SEP 16,3 SEP 2,61 SEP . SEP 10 SEP 6 SEP tb citrate SEP 10 7 SEP 15 SEP 12,7 SEP r SEP SEP 0,8605 tb SEP 10 8 SEP 6 SEP 12,5 tb Table 4. Anti angina activity . Amplitude increase protection of the T wave by vasopression in the conscinus dog.EMI16.2 tb SEP Treatment SEP Weight SEP Dose SEP iv. SEP Control SEP quot SEP t SEP tb SEP kg. SEP mg kg SEP treatment SEP student SEP Prot. tb SEP ITA SEP 362 SEP 14,0 SEP 1 SEP 1,893 SEP 0,025 SEP 46,8 tb SEP maleate SEP SEP 1,2 tb SEP Nitroglyc SEP 15,3 SEP 0,4 SEP 1,520 SEP n.s. SEP 28,9 tb SEP 1 SEP 1,2 SEP tb erine SEP at SEP SEP 1,2 tb Table 5. Anti arrythmic activitV. Fibrillation by chloro form in the male NMRI mouse. Route p.o.EMI17.1 tb Treatment SEP Dose.p.o. SEP No. SEP of SEP SEP protection SEP ED SEP and SEP con tb SEP mg kg SEP animals SEP versus SEP fibrillat SEP fidence SEP limits tb SEP ion. SEP p 0,05 SEP tb Control SEP 25 SEP ml kg SEP 20 SEP 15 tb SEP 100 SEP 20 SEP 55 tb SEP 50 SEP 20 SEP 55 tb ITA SEP 362 SEP 25 SEP 20 SEP 45 SEP 43,21 tb citrate SEP 12,5 SEP 19 SEP 31,6 SEP tb SEP 6,25 SEP 19 SEP 42,1 tb SEP 3,125 SEP 20 SEP 10 tb SEP 100 SEP 20 SEP 70 tb ITA SEP 362 SEP 50 SEP 20 SEP 70 SEP 35,4 tb maleate SEP 25 SEP 20 SEP 35 SEP 27,52 tb isomer SEP A SEP 12,5 SEP 20 SEP 25 SEP 45,42 tb SEP 100 SEP 20 SEP 85 tb ITA SEP 362 SEP 50 SEP 20 SEP 45 SEP 27,60 tb maleate SEP 25 SEP 20 SEP 55 SEP SEP 16,39 SEP tb isomer SEP B SEP 12,5 SEP 20 SEP 35 SEP SEP 45,48 SEP tb calculation is not possible Table 6. Anti arrythmic activity. Fibrillation by chloro form in the male NMRI mouse. Route i.p. EMI18.1 tb Treatment SEP Dose SEP i.p. SEP No. SEP of SEP SEP protection SEP ED SEP and SEP con tb SEP mg kg SEP animals SEP versus SEP fibrillation SEP fidence SEP limits tb SEP p 0,05 SEP tb Control SEP 25 SEP ml kg SEP 20 SEP 5 tb SEP 100 SEP 20 SEP 89,5 SEP 34,0 tb Amiodar SEP 50 SEP 20 SEP 52,6 SEP 21,4 SEP tb SEP ona SEP 25 SEP 20 SEP 45 SEP 54,0 tb SEP 100 SEP 20 SEP 84,2 tb ITA SEP 362 SEP 50 SEP 20 SEP 35 SEP 41,4 tb citrate SEP 25 SEP 20 SEP 40 SEP 27,1 SEP tb SEP 12,5 SEP 20 SEP 25 SEP 63,2 tb SEP 100 SEP 20 SEP 70 tb ITA SEP 362 SEP 50 SEP 20 SEP 60 SEP 35,3 tb maleate SEP 25 SEP 20 SEP 35 SEP 20.17 tb isomer SEP A SEP 12,5 SEP 20 SEP 35 SEP 61,98 tb SEP 100 SEP 20 SEP 95 tb ITA SEP 362 SEP 50 SEP 20 SEP 70 SEP 24,5 tb maleate SEP 25 SEP 20 SEP 35 SEP SEP 16,11 SEP tb isomer SEP B SEP 12,5 SEP 20 SEP 40 SEP 37,20 tb DOSAGEThe daily dose of the active pharmaceutical product may vary over a wide margin between 5 and 1000 mg depending on the therapeutic application and the form of administration.FORMS OF ADMINISTRATIONThe new product ITA 362 described above and obtained by means of the method of preparation object of this present invention may be administered under the various conventional forms as for example by tablets, dragees, capsules or in suspension with a view to administration by via oral or by intravenous injection.The pharmaceutical specialty contains the active compound and one or other of the acceptable pharmaceutical vehicles as well as auxiliary non toxic substances such as dispersal agents, compacting agents, emulsifiers, preservatives, humectants or others with particularly desirable specific prop erties. As non limititive illustrative examples of suitable pharmaceutical specialties containir.a the active product prepared according to the method object of this invention are the following Example 8. Capsules. Containing 200 mg of active ingredient.1 Capsule No. 1 2 2 benzofuranil 4 butylaminomethyl 2 p chlorophenyl 1, 3 dioxolane, maleate 200 mgLactose USP USP United States Pnarmacopea 45 mgMagnesium stearate 5 mg 250 mg Example 9. TabletsTablets with 25 mg of active ingredient 2 2 benzofuranil 4 butylaminomethyl 2 p chlorophenyl l, 3 dioxolane, maleate 25 mgStarch USP 2,5 mgTalc. USP 2 mgMagnesium stearate 0,5 mg 30 mgTHERAPEUTIC APPLICATIONSThe use of this compound is recommended for the treatment of angina pectoris, stenocardia and acute visceral pain. Prophylaxis of the effort, stress, and nocaturnal anaor. Treatment in the recuperation stage . of miocardiac infarct.Ventricular insufficiency of left side congestion, . Pulmonary oedema. Heart surgery. Anaesthesia. Supra ventricular and ventricular arrythmia or arrythmia resistant to the classic treatments, Sinus tachycardia and paroxysmal tachycardia, auricular and flutter fibrillation, nodal and ventricular tachycardia, ventricular and auricular extrasystoles and the WolfParkinson White syndrome.